The research behind Predipet
Predipet’s assays are developed by a research team at The Swedish University of Agricultural Sciences (SLU) lead by Professor Staffan Eriksson.
The research is focused on deoxynucleotide, which are the building blocks of DNA, and especially on the enzyme thymidine kinase (TK1) as a biomarker of cancer diseases. It is previously known that TK1 is released into the bloodstream in case of tumor growth. There is also evidence that this can happen even in case of pre-cancerous conditions.
A scientific breakthrough occurred when Staffan Eriksson’s team developed an immunochemical method for measuring TK1 in the blood. The method offer great benefits compared to previously established methods for determining TK1. It is unique and patented in EU/USA/CAN/AUS/JPN.
Predipet Canine
Test for early detection, monitoring and screening of tumor diseases in dogs, currently only available in Sweden and Scandinavia
Predipet Feline
Assay for early detection, monitoring and screening of tumor diseases in cats. Under development, expected late 2025
Predipet Equine
Assay for early detection, monitoring and screening of tumor diseases in horses. Under development, expected 2026
